Fallopian tube cancer is rare, accounting for about 1% of gynecologic cancers. It behaves much like ovarian cancer and is now often grouped with it under the umbrella of high-grade serous carcinoma. Most cases are found at advanced stages, when cancer has spread beyond the tubes, and treatment typically involves surgery followed by platinum-based chemotherapy.
What's actually going on in research
Trials are testing PARP inhibitors for BRCA-mutated cancers, antibody-drug conjugates that deliver chemotherapy directly to tumor cells, immune checkpoint inhibitors alone and combined with chemotherapy, and new platinum doublets. Researchers are also studying earlier detection methods and whether removing fallopian tubes in high-risk women prevents cancer.
PARP inhibitors
Olaparib and other PARP inhibitors are FDA-approved for maintenance after chemotherapy in BRCA-mutated ovarian and fallopian tube cancers. Trials are testing them in earlier treatment lines and in combination with other drugs.
Antibody-drug conjugates
Mirvetuximab soravtansine was approved in 2022 for folate receptor-alpha positive cancers. Other antibody-drug conjugates are in trials, aiming to deliver chemotherapy more precisely to cancer cells while sparing healthy tissue.
Immunotherapy combinations
Checkpoint inhibitors haven't worked well alone in most ovarian and fallopian tube cancers. Trials are testing them combined with chemotherapy, PARP inhibitors, or VEGF inhibitors to see if combinations overcome resistance.
What to know before you search
Eligibility typically depends on cancer stage, BRCA or HRD mutation status, how recently you completed chemotherapy, and whether your cancer is platinum-sensitive or platinum-resistant.
What types of trials are currently open
- Maintenance trials — Testing drugs like PARP inhibitors or immunotherapy given after chemotherapy to keep cancer from returning or progressing.
- Combination trials — Studies pairing chemotherapy with targeted drugs like bevacizumab or checkpoint inhibitors to improve initial treatment response.
- Recurrence trials — Testing new drugs or combinations for cancers that have returned after prior treatment, often focusing on platinum-resistant disease.
- Biomarker trials — Enrolling people based on tumor features like BRCA mutations, HRD status, or folate receptor expression to test matched therapies.
- Prevention trials — Studying whether removing fallopian tubes in women at high genetic risk prevents cancer from developing.
Recently added Fallopian Tube Cancer trials
Receive a uterine lavage procedure to screen for ovarian cancer risk
This clinical trial develops a non-surgical approach using uterine lavage samples to screen for progression to ovarian cancer in high-risk patients carrying BRCA mutations. Women with inherited mutations in the BRCA1 and BRCA2 genes (BRCA carriers) have a much higher lifetime risk of developing ovarian cancer. Currently there are no effective ovarian cancer screening or early detection tests for BRCA carriers. Uterine lavage is a procedure that uses saline to rinse and collect cells from the fallopian tube. Molecular analysis of these samples may help proactively detect genetic alterations that are indicative of progression to ovarian cancer in women with BRCA mutations.
Share your treatment data in a gynecologic cancer registry
REGYNERA(dia)TION is an international, multicenter, ambispective observational patient registry of adults with recurrent gynecologic malignancies after prior radiotherapy who are treated or planned for reirradiation and/or total ablative strategies as part of routine clinical care. The registry does not assign treatment. Radiotherapy technique, dose, systemic therapy, surgery, metastasis-directed therapy, imaging, and follow-up are selected by the treating multidisciplinary team according to local standards and patient-specific factors. The registry will collect harmonized retrospective and prospective data on disease characteristics, prior radiotherapy, recurrence pattern, reirradiation or ablative treatment exposure, response, progression, survival, severe treatment-related morbidity, fistula events, and patient-reported outcomes where available.
Find Fallopian Tube Cancer trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.